The nonstructural protein 5A (NS5A) of the hepatitis C virus (HCV) has been shown to interact with a variety of cellular proteins and implicated in the regulation of cell growth, interferon resistance, and other cellular signaling pathways, but the role of NS5A in HCV pathogenesis has not been firmly established. To further characterize this multifunctional protein, we instigated the studies of the subcellular localization of NS5A in a hepatoma cell line. NS5A was localized to the perinuclear membrane structures, including the endoplasmic reticulum (ER) and the Golgi apparatus, by immunofluorescence staining and confocal microscopy. In addition, it was also associated with the surface of cytoplasmic globular structures when expressed alone or as a part of the NS3-5B polyprotein. Oil red O staining revealed that these globular structures were lipid droplets, where the HCV core protein was also localized. The association of NS5A with intracellular membrane was further confirmed by membrane flotation analysis. To determine whether NS5A interacts with any cellular lipid-binding protein, we performed yeast two-hybrid screening in both HepG2 and human liver cDNA libraries. Apolipoprotein A1 (apoA1), one of the protein components of high-density lipoprotein (HDL) particles, was identified by two independent screening processes. The interaction between NS5A and apoA1 was confirmed by both in vitro pull-down and in vivo coimmunoprecipitation experiments. Immunofluorescence staining revealed a significant colocalization of NS5A and apoA1 in the Golgi apparatus. Our results established an association of NS5A with lipid droplets and apoA1, suggesting that NS5A, together with the core protein, may play a role in the pathogenesis of the derangement of lipid metabolism, contributing to liver steatosis commonly observed in hepatitis C. © 2002 Elsevier Science
INTRODUCTION
Hepatitis C virus (HCV) has emerged in the recent years to be an important human pathogen associated with non-A, non-B hepatitis. HCV infection is prevalent in about 2% of the world population and is the leading cause of chronic hepatitis and liver cirrhosis. As a member of the Flaviviridae family, HCV contains a positivesense, single-stranded RNA genome of approximately 9.5 kb. The viral genome encodes a single polyprotein of about 3010 amino acids, which is proteolytically processed by a combination of host-and virus-encoded proteases into at least 10 viral structural and nonstructural (NS) proteins arranged in the order of (NH 3 )-C-E1-E2-p7-NS3-NS4A-NS4B-NS5A-NS5B-(COOH) (Grakoui et al., 1993; Lohmann et al., 1996) . Most of the nonstructural proteins (NS2-5B) are probably involved in viral replica-tion; for example, NS2, NS3, and NS4A have proteolytic activities, whereas NS5B is an RNA-dependent RNA polymerase responsible for HCV RNA replication. But the possible functions of NS4B and NS5A remain enigmatic.
NS5A is a phosphoprotein (Tanji et al., 1995) , which appears to possess multiple and diverse functions in HCV replication, interferon (IFN) resistance, and HCV pathogenesis. Based on the studies using a subgenomic HCV replicon, NS5A has recently been implicated in viral RNA replication (Blight et al., 2000) . We have previously shown that NS5A and NS5B together bind to a human vesicle-associated membrane protein (VAMP)-associated protein of 33 kDa (hVAP33), suggesting that NS5A may be part of the membrane-associated viral replication complex (Tu et al., 1999) . NS5A contains a putative nuclear localization signal, although the full-length NS5A is retained in the cytoplasm (Ide et al., 1996) . The N terminus truncated, but not the full length; NS5A is a potent transcriptional activator (Chung et al., 1997; Kato et al., 1997; Tanimoto et al., 1997) . However, whether this transactivation activity is related to HCV RNA synthesis is not clear. Interestingly, a recent report has indicated that the full-length NS5A can be cleaved by cellular caspase-like proteases into the truncated forms that possess transactivation activity (Satoh et al., 2000) .
NS5A has been proposed to contain an interferonsensitivity-determining region (ISDR) in the central part of the protein, which may be one of the determinants of the response to IFN treatment in patients infected with certain genotype 1b isolates (Enomoto et al., 1996; Fukuma et al., 1998) . This region has also been found to mediate the binding of NS5A to the IFN-inducible doublestranded (ds) RNA-dependent protein kinase (PKR), an immediate early effector of the cellular antiviral response induced by IFN (Gale et al., 1998) . NS5A from IFN-resistant strains of HCV genotypes 1a and 1b can repress the actions of PKR, whereas mutations within the ISDR, which were identified in IFN-sensitive strains of HCV, rendered NS5A inactive. Recently, NS5A has been shown to induce a CXC chemokine, interleukin 8, leading to a partial inhibition of the antiviral effects of IFN . Thus, it appears that NS5A employs at least two different mechanisms to counteract the effects of IFN. In addition, NS5A may have a direct effect on the pathogenesis of HCV-associated liver disease. For example, NS5A contains antiapoptotic and oncogenic activities, which may contribute to the development of HCC Ghosh et al., 2000a Ghosh et al., , 1999 . These oncogenic potentials of NS5A can be attributed to its interaction and inhibition of the tumor suppressor proteins, PKR and p53 (Majumder et al., 2001) . However, a recent study found no effects of NS5A on dsRNA-induced apoptosis . Furthermore, NS5A interacts with growth factor receptorbound protein 2 (Grb-2) adaptor protein (Tan et al., 1999) , a cellular transcription factor Snf2-related CREB (cAMP receptor-binding protein)-binding protein activator protein (SRCAP) (Ghosh et al., 2000b) , and karyopherin ␤3 (Chung et al., 2000) , and, thus, may perturb various cellular signaling and metabolic pathways and contribute to HCV-related liver disease.
The potential interaction of NS5A with so many different cellular proteins suggests that NS5A could be widely distributed inside the cells. Previous studies have suggested an association of NS5A with the ER and the Golgi (Polyak et al., 1999; Tu et al., 1999) , which is consistent with its possible role in HCV replication (Blight et al., 2000; Pietschmann et al., 2001) . However, this localization will not likely explain all of the purported functions of NS5A. Moreover, the subcellular localization of NS5A has not been studied extensively in hepatocytes, the natural reservoir for HCV infection. We, therefore, performed systematic studies of the subcellular localization of NS5A by confocal microscopy in a hepatoma cell line, HuH7. We found that NS5A was localized not only to the ER and the Golgi apparatus, but was also colocalized with the HCV core protein on cytoplasmic lipid droplets. Furthermore, it could interact with apolipoprotein A1 (apoA1), which is a component of HDL particles. There-fore, NS5A appears to be capable of interacting with multiple components of cellular lipid metabolic pathways, and, together with the core protein, may thus contribute to HCV-associated steatosis.
RESULTS
NS5A colocalizes with the HCV core protein on lipid droplets in addition to the ER and the Golgi apparatus
To explore the potential roles of NS5A in HCV pathogenesis, we examined the subcellular localization of NS5A in the context of other NS proteins by immunofluorescence staining and confocal microscopy in a human hepatoma cell line, HuH7. HuH7 cells transfected with pSI/NS3-5B, which expresses NS3 through NS5B, were fixed under a condition that better preserves the lipid architecture of the cells. The localization of NS5A was determined by immunostaining with a monoclonal antibody against NS5A. Calreticulin (Stendahl et al., 1994) and the beta coat protein (␤cop) (Waters et al., 1991) were used as markers for the ER and the Golgi apparatus, respectively. Similar to NS5A alone (Polyak et al., 1999) (data not shown), NS5A expressed as a part of the NS polyprotein was localized to the ER (Figs. 1a-d) as well as the Golgi apparatus . This result is consistent with the previous findings that NS5A binds to hVAP33, which is mainly localized to the ER and the Golgi apparatus (Tu et al., 1999) , and that NS5A is part of the HCV replication machinery (Blight et al., 2000; Pietschmann et al., 2001) , which is likely membrane bound. Interestingly, NS5A was also found on the circumference of distinct globular structures, which were not stained by the ER marker (arrows in Figs. 1a-d). These structures collapsed when the cells were subjected to acetone treatment (data not shown), but were not affected by low concentrations of detergent, such as 0.1% Triton X-100, suggesting that these structures may contain lipids.
Previous reports have shown that the HCV core protein is associated with lipid droplets in several cell lines, including HepG2 (Barba et al., 1997; Hope and McLauchlan, 2000) . The contents of these droplets were determined to be mainly triacylglycerols and/or cholesterol esters (Barba et al., 1997) , which can be identified by oil red O staining (Hope and McLauchlan, 2000; Ramirez-Zacarias et al., 1992) . We, therefore, stained the cells with oil red O to see whether these globular structures were lipid droplets. Indeed, the periphery as well as the contents of these structures were intensely stained with oil red O, indicating that they are most likely lipid droplets ( Fig. 2A, a-d ). In cells that contain abundant lipid droplets, the association of NS5A with lipid droplets was even more prominent than that with the ER or the Golgi. Similarly, some of the HCV core protein was also shown to be associated with the surface of lipid droplets ( Fig. 2A , e-h). When NS5A and the core protein were coexpressed, they displayed a significant colocal-ization on the surface of lipid droplets (Fig. 2B, a-d ). In these cells, the fluorescence intensity was lowered to ensure a discernible demonstration of NS5A on lipid droplets, but the relatively fainter staining on other structures, such as the ER, could not be shown clearly under this condition.
We also examined the localization of core and NS5A in BHK21 and CHO cells, which have fewer and smaller lipid droplets. The expression of the core protein increased the number of lipid droplets in these two cell lines (data not shown), consistent with the previous findings in CHO cells (Barba et al., 1997) . When coexpressed with the core protein in BHK21 cells, NS5A colocalized with core on the surface of lipid droplets ( Fig. 2B , e-h, arrowheads). NS5A alone, however, did not induce the appearance of lipid droplets. Instead, it exhibited a more diffuse pattern predominantly in the perinuclear region, most likely being associated with the ER and the Golgi (Fig. 2B , f and h, arrows). We did not observe an apparent synergism between NS5A and core in terms of induction of lipid droplets. Similar results were also obtained in CHO cells (data not shown). When NS5A was expressed as part of the NS3-5B polyprotein in HuH7 cells, it was detected on the surface of lipid droplets as well (note yellow rings in Fig. 3d ). In contrast, neither NS3 (Figs. 3e-h) nor NS5B (data not shown) colocalized with lipid droplets. Taken together, these findings indicate that NS5A colocalizes with the core protein on the surface of lipid droplets in both hepatic and nonhepatic cell lines.
Association of NS5A with membrane fractions
Immunofluorescence staining and confocal analysis indicated that NS5A is localized to cytoplasmic membrane structures, such as the ER and the Golgi as well as lipid-containing structures, such as lipid droplets. To confirm the association of NS5A with lipid-containing membranes, we performed membrane flotation analysis to separate membrane and cytosolic fractions as previously described (Sanderson et al., 1994) . The membranecontaining materials float to the top of the sucrose gradient, while the cytosolic fractions remain at the bottom. The sucrose gradient was collected from the top to the bottom into nine fractions. The presence of NS5A in each fraction was determined by immunoblotting using the monoclonal anti-NS5A antibody. As shown in Fig. 4A , NS5A was found predominantly in the membrane fraction (fraction 2). The core protein was also detected in both membrane and cytosolic fractions as previously reported (Matsumoto et al., 1996) , but cotransfection of core with NS5A did not change the distribution of NS5A in different fractions (data not shown). An ER marker, glucose-regulated protein 78 (GRP78) (Munro and Pelham, 1986 ) was found to be located in the membrane fraction ( Fig. 4A , fraction 2) and also in the cytosolic fractions (fractions 6-9). When the cell lysates were treated on ice with 1% NP-40, a nonionic detergent, GRP78 was only observed in the cytosolic fractions ( Fig.  4B) , indicating a complete release of the ER-resident protein upon membrane disruption. In contrast, only a small percentage of the NS5A protein dissociated from the membrane and moved to the cytosolic fractions ( Fig.   FIG. 1 . The subcellular localization of NS5A in HuH7 cells. HuH7 cells were transfected with the construct expressing the NS3-5B polyprotein, pSI/NS3-5B. Two days after transfection, the cells were double stained with either the rabbit polyclonal antibody against the ER marker, calreticulin (a), or the rabbit polyclonal antibody against the Golgi marker, ␤cop (f), and the monoclonal antibody against NS5A (b, e). The arrows indicate the localization of NS5A on cytoplasmic globular structures. The superimposed images are shown in (d) and (h). The phase contrast images are shown in (c) and (g). Bar: 5 m.
4B, fractions 6 and 7), suggesting that NS5A is largely present in detergent-insoluble complexes. This observation is consistent with the recent finding that proteins localized on lipid droplets are insoluble in cold nonionic detergents (Pol et al., 2001) . These results provide biochemical evidence that NS5A is associated with intracellular membrane structures, including lipid droplets.
Identification of apoA1 as an NS5A-binding protein by yeast two-hybrid screening
The association of NS5A with lipid droplets suggests that NS5A may interact with components of lipid metabolic pathways. To identify such components, we performed two independent yeast two-hybrid screenings to FIG. 2. NS5A colocalizes with the HCV core protein on lipid droplets. (A) Colocalization of NS5A and core on lipid droplets. HuH7 cells were transfected with pcDNA3.1/NS5A or pcDNA3.1/core. Two days after transfection, the cells were stained with the mouse monoclonal antibody against NS5A (b) or the rabbit polyclonal antibody against core (f), respectively. Lipid droplets were stained with oil red O (a and e) after immunostaining. (B) Colocalization of NS5A and core. HuH7 (a-d) and BHK21 (e-h) cells were cotransfected with pcDNA3.1/NS5A and pcDNA3.1/core using the FuGene 6 transfection reagent. Two days after transfection, the cells were double stained with the rabbit polyclonal antibodies against core (a and e) and the mouse monoclonal antibody against NS5A (b and f). The superimposed images are shown in (d) and (h). The phase contrast images are shown in (c) and (g). Bar: 5 m.
identify cellular proteins that can interact with NS5A. When NS5A of genotype 1a was used as the bait to screen a HepG2 cDNA library, seven positive clones were obtained (Tu et al., 1999) , one of which was identified as human apoA1. The previously reported NS5Abinding protein, hVAP-33, was also identified by the same screening (Tu et al., 1999) . The other screening using NS5A of genotype 1b as the bait in a human liver cDNA library resulted in 12 positive clones, three of which were apoA1. ApoA1 is one of the major protein components of the HDL particles (Fruchart and Ailhaud, 1992) . The other protein component of HDL is apoA2, which has been shown to interact with the HCV core protein (Sabile et al., 1999) . The function of apoA2, however, is still not clear.
The specificity of the interaction between NS5A and apoA1 was further verified by cotransformation of yeast with the pACT-2/apoA1 clone and various NS5A genotype 1b constructs in plasmid pAS2-1 ( Fig. 5 ). As expected, apoA1 interacted with the full-length NS5A. Deletion of the C-terminal 44 amino acids (aa) of NS5A (NS5A-⌬C) or of the ISDR (NS5A-⌬ISDR) did not affect the binding to apoA1. The N-terminal 224 aa of NS5A (N-NS5A) alone was sufficient for binding. In contrast, ISDR alone (ISDR) did not interact with apoA1. As negative controls, the plasmid vector containing the GAL4 DNA-binding domain (BD) alone or lamin C did not interact with apoA1. Some truncated NS5A constructs containing the DNA-binding domain have only been shown previously to activate ␤-gal in the absence of the activation domain (AD) construct (Chung et al., 1997; Kato et al., 1997; Tanimoto et al., 1997) , but no autonomous activation was observed for the NS5A constructs used in this study (data not shown).
NS5A interacts with apoA1 in vitro
To confirm that HCV NS5A can interact with apoA1 directly, we performed GST-pull-down assays in vitro. The full-length apoA1 and three truncation mutants (⌬1, ⌬2, and ⌬3) were expressed as GST-fusion proteins and incubated with in vitro translated, 35 S-labeled NS5A. As shown in Fig. 6A , GST-apoA1 (lane 3), but not GST alone (lane 2), was able to pull down NS5A. Interestingly, apoA2, which is another protein component of the HDL particles and interacts with the HCV core protein, also bound NS5A, although the interaction was weaker than that between NS5A and apoA1 (lane 7). Computer-aided analysis showed that apoA1 and apoA2 contain homologous amino acid sequences, which may explain the binding of NS5A to both apolipoproteins (Shelley et al., 1985) . No interaction was detected between NS5B and apoA1 or A2 (lanes 8-10), indicating that the in vitro interactions between NS5A and apolipoproteins are specific.
ApoA1 consists of repetitive 22-aa segments that form amphipathic alpha helices, capable of lipid and protein binding (Segrest et al., 1992) . The N-terminal aa 43-126 of apoA1 has been shown to be responsible for proteinprotein interaction (Jonas et al., 1990) , whereas the Cterminal aa 190-243 is critical for lipid binding, selfassociation, and lipoprotein interaction (Ji and Jonas, 1995; Schmidt et al., 1995; Segrest et al., 1992) . Moreover, the helical structures throughout the apoA1 protein are influenced by changes in other parts of the protein and by lipid binding (Davidson et al., 1996) . To determine which region of apoA1 is responsible for NS5A binding, three truncated constructs of apoA1 ( Fig. 6) were used in GST-pull-down assay. Truncation of the N-terminal 66 aa of apoA1 (apoA1⌬2) did not affect its binding to NS5A (Fig. 6A , lane 5), whereas deletion of the C-terminal 76 aa only slightly reduced the binding (apoA1⌬1, lane 4), suggesting that the middle domain is the NS5A-binding sequence. However, the central domain of apoA1 (apoA1⌬3) alone binds to NS5A only weakly, suggesting that the neighboring sequences are also important for maintaining the NS5A-binding properties.
NS5A interacts with apoA1 in mammalian cells
To demonstrate the potential interaction of NS5A with apoA1 in cells, we performed coimmunoprecipitation experiments for NS5A and apoA1 in Cos7 cells. The Flag-tagged NS5A was coexpressed with apoA1 from T7-expression plasmids, coupled with infection with recombinant vaccinia viruses (vTF7-3) expressing T7 polymerase. Cell lysates were immunoprecipitated with the monoclonal anti-Flag antibody (M2 beads). The immunoprecipitates were separated by SDS-PAGE, followed by immunoblotting with a goat polyclonal anti-apoA1 antibody. ApoA1 was shown to coimmunoprecipitate with Flag-NS5A (Fig. 7, lane 4) , but not NS5B (lane 5), although the expression of Flag-NS5B was comparable to that of Flag-NS5A. When apoA1 was expressed alone, it could not be precipitated by the anti-Flag antibody (lane 3). These results further demonstrate that apoA1 can specifically interact with NS5A in mammalian cells.
Colocalization of NS5A with apoA1 in HuH7 cells
The results shown above indicate that NS5A can interact with apoA1 both in vitro and in vivo. To evaluate the possibility of such an interaction in intact cells, we examined the subcellular localization of apoA1 with NS5A by immunostaining. Because the level of intracellular apoA1 was too low, probably as a result of rapid secretion, to produce an unequivocal staining, apoA1 or A2 was cotransfected with Flag-NS5A into HuH7 cells. Both apoA1 and A2 were found to be clustered in the perinuclear region and colocalized with the Golgi complex (data not shown), which is consistent with the previous finding that apoA1 is predominantly associated with the trans-Golgi network (Banerjee et al., 1997) . We did not detect any colocalization of apoA1 or A2 with lipid droplets. However, both of them were colocalized with a portion of NS5A (Fig. 8) , most likely on the Golgi apparatus, supporting a possible interaction between NS5A and these two apolipoproteins. Under the same condition, NS5A was also detected on the surface of lipid droplets ( Figs. 8a-d, arrows) . Similar results were obtained in BHK21 cells or when NS5A was expressed as a part of the NS3-5B polyprotein (data not shown). These results confirmed that only a portion of the intracellular pool of NS5A is associated with apoA1 and apoA2 on the Golgi apparatus, which is consistent with the multifunctional nature of NS5A.
DISCUSSION
HCV infection is often associated with the occurrence of liver steatosis (Baiocchi et al., 1998; Fujie et al., 1999) . The involvement of HCV core protein in the development of steatosis has been suggested by its localization on lipid droplets and its interaction with apoA2 (Barba et al., 1997; Sabile et al., 1999) . In this report, we showed that NS5A could be another HCV protein that plays a role in HCV-associated liver steatosis. NS5A is colocalized with the HCV core protein on lipid droplets and interacts with apoA1, which is a lipid-binding protein and one of the major components of HDL particles. These properties suggest that NS5A may affect cellular lipid metabolism by at least two different mechanisms, and that NS5A, together with core, may contribute to the development of liver steatosis.
Earlier studies have reported that NS5A is localized to cytoplasmic membrane structures (Kim et al., 1999; Polyak et al., 1999; Selby et al., 1993; Tu et al., 1999) , but the exact localization of NS5A has not been determined. In this study, we identified these membranes as the ER and the Golgi apparatus by immunofluorescence staining. Furthermore, both cytological and biochemical studies showed that NS5A was also present on lipid droplets. Previous failures to identify such an association could have been due to the disruption of lipid droplets by acetone or methanol in the fixation procedures. In fact, the core protein was associated only with the ER membrane when it was expressed in cells grown in lipiddeficient medium (Hope and McLauchlan, 2000) . In addition, the localization of NS5A in HuH7 cells was also affected by the differences in number, size, and distribution of lipid droplets. In cells where most of the cytoplasm was occupied by large lipid droplets, the NS5A signal was found to be concentrated on the surface of lipid droplets (e.g., Figs. 2A, a-d) . A relatively smaller amount of NS5A was associated with the ER and the Golgi in these cells, which could be seen only when the fluorescence intensity was enhanced.
Electron microscopy of the HuH7 cells containing a self-replicating subgenomic replicon revealed an asso-ciation of HCV NS proteins with the ER, but not with lipid-containing vesicles (Pietschmann et al., 2001) . However, in that study, a mixture of the antibodies against several NS proteins were used; thus, it is not clear whether NS5A was specifically detected. It is also possible that the localization of NS5A is dependent on other cellular conditions. The exact nature of this difference remains to be clarified. Regardless, the wide distribution of NS5A in different subcellular components is consistent with its purported multiple functions.
Lipid droplets occur in all mammalian cell types and serve as energy storage sites (Brown, 2001; van Meer, 2001) . They consist of a core of triacylglycerols and cholesterol esters, which is synthesized in the ER, surrounded by a phospholipid monolayer, which is also derived from the ER (Brown, 2001; van Meer, 2001) . A number of proteins, such as perilipin (Blanchette-Mackie et al., 1995) , adipophilin (Brasaemle et al., 1997) , TIP47 (Wolins et al., 2001) , and caveolin (Fujimoto et al., 2001; Ostermeyer et al., 2001; Pol et al., 2001) , have been shown to be present on the surface of lipid droplets. Binding of proteins to lipid droplets is probably hydrophobic in nature as it was resistant to the treatment of cold nonionic detergents (Pol et al., 2001) or carbonate (Wolins et al., 2001) .
Presumably, these lipid droplet-associated proteins play key roles in the structure and function of lipid droplets, but very little is known about them. A recent study reported that perilipin could regulate the number, distribution, and contents of lipid droplets (Brasaemle et al., 2000) . Significantly, we found that the association of NS5A with membrane structures was also resistant to detergent treatments. It is not clear whether NS5A or core interact with the lipid droplets by directly binding to the lipids or through the interactions with other surface proteins. Conceivably, these HCV proteins may also affect the structure and function of lipid droplets. We indeed observed an increase in the number of lipid droplets upon the expression of the HCV core protein as previously shown by Barba et al. (1997) . In contrast, NS5A did not appear to possess the ability to induce the formation of lipid droplets. As a result, when NS5A alone was expressed in BHK21 cells, it was localized in the perinuclear region, most likely to be associated with the ER and the Golgi (Fig. 2B) . Nevertheless, NS5A still showed strong affinity for the lipid droplets induced by the expression of core in cells coexpressing NS5A and core. There was no gross difference observed with the lipid droplets in cells expressing core alone or coexpressing NS5A and core; however, it cannot be ruled out that NS5A can affect the stability or change the contents of the core-induced lipid droplets. More studies are needed to understand the functions of NS5A in lipid droplet formation.
ApoA1 is mainly synthesized and actively secreted by the liver (Brouillette and Anantharamaiah, 1995) . It is one of the major protein components of the HDL particles, whose major lipid components consist of triacylglycerols and cholesterol esters. The primary function of apoA1 and HDL is the regulation of serum cholesterol levels by transporting cholesterol from peripheral tissues to the liver through a process known as reverse cholesterol transport (Fruchart and Ailhaud, 1992) . Furthermore, apoA1 and apoA2 have been shown to regulate hepatic lipase-mediated hydrolysis of triacylglycerols and phospholipids in HDL particles (Boisfer et al., 1999; Hime et al., 1998 Hime et al., , 2001 Mowri et al., 1996 Mowri et al., , 1992 Shinomiya et al., 1982; Weng et al., 1999; Zhong et al., 1994) . Because triacylglycerols, cholesterol esters, and/or phospholipids are also the components of lipid droplets as indicated by oil red O staining, apoA1 and apoA2 may affect the formation and composition of lipid droplets through the regulation of intracellular metabolism of fatty acids. The HCV proteins, NS5A and core, may, in turn, have an effect on lipid metabolism through their interactions with apoA1 and apoA2. Although we did not observe a localization of apoA1 or apoA2 on lipid droplets, it is still possible that a small amount of them is present, which can directly influence the properties of lipid droplets. Indeed, detection of a fraction of apoA1 in other parts of the cytoplasm has been documented previously (Hamilton et al., 1990) . Alternatively, NS5A may interact with yet another unidentified lipid-binding molecule. Regardless of the mechanism, the fact that NS5A interacts with lipids and lipoproteins strongly suggests that it may change lipid homeostasis in hepatic cells, leading to the development of liver steatosis.
Intriguing evidence from clinical studies of alcoholinduced liver disease indicates that serum apoA1 levels change with disease progression, with an elevation observed in patients with steatosis, a reduction in those with fibrosis, and a further decline in those with cirrhosis (Poynard et al., 1995) . Hepatic steatosis has also been recognized as a characteristic of HCV infection and reinfection after liver transplantation (Baiocchi et al., 1998) . A recent evaluation of blood lipid composition in patients with chronic hepatitis C treated by IFN showed that the levels of apoA1 and HDL are independent predictive factors for response to treatment (Soardo et al., 1995) . Overall, these results suggest that hepatic lipid metabolism is a potential target for HCV proteins in viral pathogenesis. Transgenic mice expressing the core protein develop liver steatosis (Moriya et al., 1998 (Moriya et al., , 1997 . The findings that both core and NS5A are colocalized on lipid droplets and that both of them interact with apoA2 in addition to the interaction of NS5A with apoA1 suggest that core and NS5A may together affect lipid metabolism and contribute to steatosis.
ApoA1 possesses extensive secondary structure in the form of alpha helices. The amphipathic nature provides apoA1 with the ability to perturb various lipid bilayers. Consequently, apoA1 has been shown to possess antiviral and immunosuppressive activities, most likely through the perturbation of cellular membranes. Antiviral functions mediated by apoA1 include inhibition of human immunodeficiency virus and herpes simplex virus-induced cell fusion Srinivas et al., 1990) , neutralization of xenotropic type C retrovirus (Kane et al., 1979) , and lysis of Trypanosoma brucei membranes (Gillett and Owen, 1992) . Another apolipoprotein, apolipoprotein-H, has been shown to bind the surface antigen of hepatitis B virus (Mehdi et al., 1994) . Furthermore, an earlier report indicated that serum lipoproteins, including HDL, could inhibit lymphocyte proliferation stimulated by lectins or allergenic cells (Morse et al., 1977) . Our finding that NS5A interacts with apoA1 and apoA2 suggests a potential perturbation of some or all of the functions of these apolipoproteins.
The association of HCV with lipids may also be important in the viral life cycle. HCV has been shown to bind low-density lipoprotein (LDL) and its receptor, very lowdensity lipoprotein (VLDL) and, to a lesser degree, HDL (Agnello et al., 1999; Thomssen et al., 1993; Wunschmann et al., 2000) . Conceivably, the interaction between NS5A and apoA1 may affect HCV binding or entering the target cells.
MATERIALS AND METHODS

Plasmid construction
For expression in mammalian cells, NS5A (genotype 1a)-coding sequence, together with a Flag sequence linked to its N terminus, was cloned into pcDNA3.1 (Invitrogen, Carlsbad, CA). The coding sequence of core (genotype 1a) was also cloned into pcDNA3.1. The Flagtagged full-length NS5B from genotype 1a used as a control in coimmunoprecipitation was constructed in pcDNA3.1. The NS3-NS5B (genotype 1b) construct expressing an NS3-NS4A-NS4B-NS5A-NS5B polyprotein was cloned into pSI (Promega, Madison, WI). ApoA1 and apoA2 were cloned into pcDNA3.1 for their expression in mammalian cells. The plasmids used for expressing glutathione S-transferase (GST) fusion proteins of apoA1 or apoA2 in Escherichia coli were constructed in the pGEX-4T-1 vector (Novagen, Madison, WI).
Antibodies
The mouse monoclonal antibodies against NS5A and NS3 were purchased from Biodesign (Saco, Maine) and Vector Laboratories (Burlingame, CA), respectively. The rabbit polyclonal antibody against the HCV core protein was a gift from Dr. Jim Ou at the University of Southern California (Los Angeles, CA). The rabbit polyclonal antibodies against calreticulin and ␤cop were obtained from Affinity Bioreagents (Golden, CO). The mouse monoclonal antibody against GRP78 was purchased from Stress-Gen (Victoria, Canada). The goat polyclonal antibody against apoA1 and apoA2 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). The mouse monoclonal antibody against apoA1 was generously provided by Dr. Carole L. Banka at the Scripps Research Institute (La Jolla, CA). The polyclonal antibody against the Flag epitope was purchased from Zymed (San Francisco, CA). The M2 beads used for the immunoprecipitation of Flagtagged proteins were obtained from Sigma (St. Louis, MO).
Immunofluorescence staining
Cells were plated in 8-well chamber slides at a density of 5 ϫ 10 4 cells per well and transfected with 0.2 g of each plasmid in each well using the FuGene 6 transfec- FIG. 4 . Membrane flotation analysis of NS5A. HuH7 cells were transfected with pcDNA3.1/NS5A and harvested 48 h after transfection. Cell lysates were fractionated by equilibrium sucrose gradient centrifugation as described in Materials and Methods. Each fraction was concentrated in an YM-10 Centricon and analyzed on a 12.5% polyacrylamide gel, followed by immunoblotting with a monoclonal antibody against NS5A or GRP78. The fractions were numbered from 1 to 9 in the order of top to bottom (light to heavy) fractions. (A) No detergent treatment. (B) Cell lysates were treated with 1% NP-40 for 20 min on ice before sucrose gradient centrifugation.
FIG. 5.
Interaction between NS5A and apoA1 in yeast. The full-length and truncation mutants of NS5A from genotype 1b were cloned into the pAS2-1 vector and transformed with pACT2-apoA1 into Saccharomyces cerevisiae Y190 cells using the lithium chloride method according to the manufacturer's instructions. The yeast cells were streaked on histidine-containing medium (ϩHIS) or histidine-deficient medium containing 25 mM 3-amino triazole (ϪHISϩ3-AT). Yeast growth was observed 4 days after transformation. NS5A-⌬C codes for a protein that lacks the C-terminal 44 aa. N-NS5A represents the N-terminal 224 aa of NS5A. pAS2-1 (empty vector) and pAS2-1-lamin C were used as negative controls. tion reagent according to the manufacturer's instructions (Roche Molecular Biochemicals, Indianapolis, IN). Two days after transfection, slides were washed in PBS and fixed in 4% formaldehyde for 20 min at room temperature, followed by 15 min in 0.1% Triton X-100 in PBS. Primary antibodies were diluted in 5% BSA and incubated with cells for 1 h at room temperature. After three washes in PBS, fluorescein-conjugated secondary antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA) were added to cells at a 1:200 dilution for 1 h at room temperature. To stain lipids, slides were rinsed in 60% isopropanol, incubated in 5 g/ml oil red O (Fisher Scientific, Pittsburgh, PA) in 60% isopropanol for 2 min at room temperature, and rinsed in 60% isopropanol again. After staining, slides were washed in PBS and mounted in ProLong Antifade (Molecular Probes, Eugene, Oregon). Confocal microscopy was performed on a Zeiss Confocal Laser Scanning Microscope LSM 510. Image analysis was performed using the standard system operating software provided with the microscope. Colocalization of green (FITC) and red (TRITC) signals in a single pixel produces yellow while separated signals remain green or red.
Membrane flotation assay
HuH7 cells in 100-mm plates were transfected with 10 g each of pcDNA3.1/NS5A, pcDNA3.1/core, or both using the FuGene 6 transfection reagent. Two days after transfection, the cells were washed twice in ice-cold PBS and harvested for membrane flotation assay as previously described (Sanderson et al., 1994) . The cells were first lysed in 1 ml of hypotonic buffer (10 mM Tris-HCl, pH 7.5, 10 mM KCl, 5 mM MgCl 2 ) and passed through a 25-gauge needle 20 times. The nuclei and unbroken cells were removed by centrifugation at 1000 g for 5 min in a microfuge at 4°C. The supernatant was separated into two 0.5-ml aliquots, one of which was incubated with 1% NP-40 on ice for 20 min. Each aliquot was then mixed with 3 ml of 72% sucrose in low salt buffer (LSB, 50 mM Tris-HCl, pH 7.5, 25 mM KCl, 5 mM MgCl 2 ). The mixture was overlaid with 4 ml of 55% sucrose in LSB, followed by 1.5 ml of 10% sucrose in LSB. The sucrose gradient was centrifuged at 38,000 rpm in a Beckman SW41Ti rotor for 14 h at 4°C. One-milliliter fractions were taken from the top of the gradient and each was concentrated by passing through a Centricon YM-10 filter unit (Milli-FIG. 6. In vitro interaction between NS5A and apolipoproteins. (A) GST-pull-down assay. ApoA1 and its truncation mutants (⌬1, ⌬2, and ⌬3) and apoA2 were expressed as GST-fusion proteins in BL21 and purified with glutathione beads. Equal amounts of these GST-fusion proteins on beads were incubated with the in vitro translated, 35 S-labeled NS5A or NS5B at 4°C for 2 h. The complexes were washed five times, eluted from the glutathione beads, and analyzed on a 12.5% SDS-PAGE. One tenth of the in vitro translated products used in GST-pull down are shown as the 10% input. The numbers below each lane show the quantitation of signals in that lane as a percentage of the 10% input. The results of the GST-pull-down assay are summarized in B. pore, Bedford, MA). The pellet was resuspended in SDS sample buffer and analyzed on a 12.5% polyacrylamide gel.
Yeast two-hybrid screening
Two independent yeast two-hybrid screenings were carried out, one of which used NS5A of genotype 1a as the bait to screen an IFN-induced human hepatocyte (HepG2) cDNA library (Tu et al., 1999) . NS5A was cloned into a yeast expression vector pGBT9, which contains the GAL4 DNA-BD (Clontech, Palo Alto, CA) to express NS5A as a DNA-BD-fusion protein. The HepG2 cDNA library was expressed as fusion proteins to an activation domain in pGAD10. The screening procedure was described previously (Tu et al., 1999) .
The second screening was performed using NS5A from a genotype 1b patient who was nonresponsive to IFN therapy as the bait to screen a human liver cDNA library. The full-length NS5A genes were cloned separately by RT-PCR from serum specimens obtained from both IFN-responsive and nonresponsive patients as described (Polyak et al., 1999) . The full-length NS5A or the ISDR only were cloned into the GAL4 DNA-BD vector pAS2-1 (Clontech). The human liver cDNA library was cloned into the AD vector pACT2. The primer pair ISDR-US1: 5Ј-CCTTCCATGGCCCACATTACAGCAGAGACG-3Ј and ISDR-DS1: 5Ј-ATCGGATCCTTATACCACCTTATTCTC-TGA-3Ј was used to amplify the ISDR using the previously amplified full-length NS5A as a template. Prior to library screening, the pAS2-1-NS5A and pAS2-1-ISDR constructs were tested for autonomous activation of reporter genes. No autonomous activation of reporter genes was observed with any of these constructs when tested on two different occasions. Saccharomyces cerevisiae Y190 cells were cotransformed with pAS2-1-NS5A plasmids and pACT2-cDNA libraries using the lithium chloride method according to the manufacturer's instructions. At least 3 million transformants were screened in each experiment. Cells were plated in medium containing 25 mM 3-amino triazole. Clones were selected based on their positivity for ␤-gal activity and growth in histidine-deficient media upon retransformation into yeast. The AD plasmids were isolated from positive clones that grew in histidine-deficient medium and contained ␤-gal activity. The cDNA inserts in these pACT2 plasmids were then sequenced and aligned with known sequences in the GenBank.
GST-pull-down assay pGEX-4T-1, pGEX-4T-1/apoA1, or pGEX-4T-1/apoA2 plasmids were transformed and expressed in E. coli BL21 (DE3) (Novagen). The GST-pull-down experiment was performed as described previously (Tu et al., 1999) . In brief, GST-fusion proteins on glutathione Sepharose-4B beads were incubated with in vitro translated, 35 S-labeled NS5A protein in 0.2 ml GST-binding buffer (40 mM HEPES, pH 7.5, 100 mM KCl, 20 mM 2-mercaptoethanol, 0.1% of NP-40) for 2 h at 4°C. The beads were washed five times with the GST-binding buffer containing 0.3% NP-40. Proteins bound to beads were eluted by boiling in Laemmli's buffer for 5 min and separated on a 10% polyacrylamide gel. The in vitro translated full-length NS5B of genotype 1a was used as a negative control.
Coimmunoprecipitation
Cos7 cells in 60-mm plates were infected with recombinant vaccinia virus vTF7-3 expressing T7 RNA polymerase at a multiplicity of infection of approximately 10 (Fuerst et al., 1986) . Two hours after infection, the cells were transfected with 5 g each of pcDNA3.1/NS5A and pcDNA3.1/apoA1 using the calcium phosphate method. pcDNA3.1/NS5B was used as a negative control. After 16 h incubation, the cytoplasmic proteins were prepared and immunoprecipitated with the monoclonal anti-Flag antibody crosslinked to Sepharose-4B beads (M2 beads, Eastman Kodak Company, Rochester, NY). The precipitates were washed five times, boiled in Laemmli's sample buffer, and run on a 12.5% polyacrylamide gel. Immu-FIG. 7. Coimmunoprecipitation of NS5A with apoA1. The Flag-tagged NS5A and apoA1 were expressed in Cos7 cells with a vaccinia virus expression system as described in Materials and Methods. The cytoplasmic extracts were prepared from the cells 16 h after transfection and subjected to immunoprecipitation with the anti-Flag M2 beads. The immunoprecipitates were separated on a 12.5% SDS-PAGE and immunoblotted with either the rabbit polyclonal antibody against Flag or the goat polyclonal antibody against apoA1. The full-length Flag-tagged NS5B was used as a negative control. One tenth of the cytoplasmic extracts used in immunoprecipitation are shown as the 10% input.
noblotting was performed using polyclonal antibodies against Flag and apoA1.
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